Pathological Complete Response and Successful Conversion Hepatectomy in Initially Unresectable Giant Hepatocellular Carcinoma Following Triple Therapy With HAIC, Bevacizumab, and Tislelizumab: A Case Report
- 1Department of Hepatobiliary Surgery Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou China
- 2The Second Clinical College of Guangzhou University of Chinese Medicine Guangzhou China
Abstract
Severe future liver remnant (FLR) deficiency frequently renders giant hepatocellular carcinoma (HCC) unresectable. We report a 48‐year‐old man with an unresectable 23.5‐cm giant HCC (Couinaud segments 4/5/8; baseline serum alpha‐fetoprotein (AFP), 1036.65 μg/L). Initially requiring an extended right trisectionectomy with an FLR/standard liver volume (SLV) ratio of only 36.58% (450 mL). Following three cycles of mFOLFOX‐HAIC, bevacizumab, and tislelizumab, restaging computed tomography (CT) showed tumor regression to 9.0 cm in maximum diameter (a 61.7% reduction), corresponding to a partial response (PR) according to the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), and a complete response (CR) according to the modified RECIST (mRECIST), an increase in FLR volume to 733 mL (FLR/SLV: 59.58%), and an AFP decline to 115.00 μg/L. Crucially, tumor clearance from segment 4 and separation from the right portal pedicle enabled surgical downstaging to a parenchymal‐sparing anatomical right anterior sectionectomy (S5/8). R0 resection was achieved, with histopathology confirming a pathological complete response (pCR; 100% coagulative necrosis). Postoperatively, serum AFP normalized to 5.60 μg/L, and the patient remains recurrence‐free at 22 months. This case illustrates that tumor regression during triple therapy may be accompanied by increased FLR volume and improved anatomical separation from the right portal pedicle, potentially enabling a more limited resection without portal vein embolization.
Related
- Early antibiotic exposure, but not late exposure, negatively affects the clinical outcomes of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma
- Real-world evidence for atezolizumab with bevacizumab for unresectable hepatocellular carcinoma: a multicentre UK Midlands cohort
- Curative Locoregional Therapy following Objective Response to Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
- ABT score based clinical model predicts prognosis in unresectable hepatocellular carcinoma treated with TACE combined with bevacizumab and sintilimab therapy
- Efficacy and safety of sintilimab plus bevacizumab with or without transarterial chemoembolization for unresectable hepatocellular carcinoma: a propensity score-matched retrospective cohort study
BibTeX
@article{ye2026pathological,
title = {{Pathological Complete Response and Successful Conversion Hepatectomy in Initially Unresectable Giant Hepatocellular Carcinoma Following Triple Therapy With HAIC, Bevacizumab, and Tislelizumab: A Case Report}},
author = {Qing Ye and Jiamin Wang and Junming He and Jianxin Peng and Huilan Zeng and Jiaqiang Mo},
journal = {Clinical Case Reports},
year = {2026},
month = nov,
doi = {10.1002/ccr3.73835},
url = {https://doi.org/10.1002/ccr3.73835},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Pathological Complete Response and Successful Conversion Hepatectomy in Initially Unresectable Giant Hepatocellular Carcinoma Following Triple Therapy With HAIC, Bevacizumab, and Tislelizumab: A Case Report
AU - Qing Ye
AU - Jiamin Wang
AU - Junming He
AU - Jianxin Peng
AU - Huilan Zeng
AU - Jiaqiang Mo
PY - 2026
DA - 2026/11/04
JO - Clinical Case Reports
DO - 10.1002/ccr3.73835
UR - https://doi.org/10.1002/ccr3.73835
AB - Severe future liver remnant (FLR) deficiency frequently renders giant hepatocellular carcinoma (HCC) unresectable. We report a 48‐year‐old man with an unresectable 23.5‐cm giant HCC (Couinaud segments 4/5/8; baseline serum alpha‐fetoprotein (AFP), 1036.65 μg/L). Initially requiring an extended right trisectionectomy with an FLR/standard liver volume (SLV) ratio of only 36.58% (450 mL). Following three cycles of mFOLFOX‐HAIC, bevacizumab, and tislelizumab, restaging computed tomography (CT) showed tumor regression to 9.0 cm in maximum diameter (a 61.7% reduction), corresponding to a partial response (PR) according to the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), and a complete response (CR) according to the modified RECIST (mRECIST), an increase in FLR volume to 733 mL (FLR/SLV: 59.58%), and an AFP decline to 115.00 μg/L. Crucially, tumor clearance from segment 4 and separation from the right portal pedicle enabled surgical downstaging to a parenchymal‐sparing anatomical right anterior sectionectomy (S5/8). R0 resection was achieved, with histopathology confirming a pathological complete response (pCR; 100% coagulative necrosis). Postoperatively, serum AFP normalized to 5.60 μg/L, and the patient remains recurrence‐free at 22 months. This case illustrates that tumor regression during triple therapy may be accompanied by increased FLR volume and improved anatomical separation from the right portal pedicle, potentially enabling a more limited resection without portal vein embolization.
SN - 2050-0904
ER -